Titre : Protéines d'inhibition de la différenciation

Protéines d'inhibition de la différenciation : Questions médicales fréquentes

Termes MeSH sélectionnés :

Duodenum
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines d'inhibition de la différenciation : Questions médicales les plus fréquentes", "headline": "Protéines d'inhibition de la différenciation : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines d'inhibition de la différenciation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-25", "dateModified": "2025-04-19", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines d'inhibition de la différenciation" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Facteurs de transcription", "url": "https://questionsmedicales.fr/mesh/D014157", "about": { "@type": "MedicalCondition", "name": "Facteurs de transcription", "code": { "@type": "MedicalCode", "code": "D014157", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Protéine d'inhibition de la différenciation de type 1", "alternateName": "Inhibitor of Differentiation Protein 1", "url": "https://questionsmedicales.fr/mesh/D051798", "about": { "@type": "MedicalCondition", "name": "Protéine d'inhibition de la différenciation de type 1", "code": { "@type": "MedicalCode", "code": "D051798", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930.329.249" } } }, { "@type": "MedicalWebPage", "name": "Protéine d'inhibition de la différenciation-2", "alternateName": "Inhibitor of Differentiation Protein 2", "url": "https://questionsmedicales.fr/mesh/D051797", "about": { "@type": "MedicalCondition", "name": "Protéine d'inhibition de la différenciation-2", "code": { "@type": "MedicalCode", "code": "D051797", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.930.329.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Protéines d'inhibition de la différenciation", "alternateName": "Inhibitor of Differentiation Proteins", "code": { "@type": "MedicalCode", "code": "D051796", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Francesco Balestri", "url": "https://questionsmedicales.fr/author/Francesco%20Balestri", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Roberta Moschini", "url": "https://questionsmedicales.fr/author/Roberta%20Moschini", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Umberto Mura", "url": "https://questionsmedicales.fr/author/Umberto%20Mura", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Mario Cappiello", "url": "https://questionsmedicales.fr/author/Mario%20Cappiello", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } }, { "@type": "Person", "name": "Antonella Del Corso", "url": "https://questionsmedicales.fr/author/Antonella%20Del%20Corso", "affiliation": { "@type": "Organization", "name": "Biochemistry Unit, Department of Biology, University of Pisa, Via S. Zeno 51, 56127 Pisa, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Automatic segmentation of colon, small intestine, and duodenum based on scale attention network.", "datePublished": "2022-07-22", "url": "https://questionsmedicales.fr/article/35833330", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mp.15862" } }, { "@type": "ScholarlyArticle", "name": "Biliary obstruction and pancreatitis after duodenal stent placement in the descending duodenum: a retrospective study.", "datePublished": "2022-05-21", "url": "https://questionsmedicales.fr/article/35597896", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12876-022-02333-7" } }, { "@type": "ScholarlyArticle", "name": "Mixed adenoneuroendocrine carcinoma of the non-ampullary duodenum with mismatch repair deficiency: a rare case report.", "datePublished": "2022-05-20", "url": "https://questionsmedicales.fr/article/35596001", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00795-022-00324-x" } }, { "@type": "ScholarlyArticle", "name": "Vitamin C Improves Dasatinib Concentrations Under Hypochlorhydric Conditions of the Simulated Stomach Duodenum Model.", "datePublished": "2022-07-01", "url": "https://questionsmedicales.fr/article/35778632", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11095-022-03321-y" } }, { "@type": "ScholarlyArticle", "name": "Obesity and overweight are linked to increased sodium-glucose cotransporter 1 and glucose transporter 5 levels in duodenum.", "datePublished": "2023-02-06", "url": "https://questionsmedicales.fr/article/36746764", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/oby.23653" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Facteurs de transcription", "item": "https://questionsmedicales.fr/mesh/D014157" }, { "@type": "ListItem", "position": 5, "name": "Protéines d'inhibition de la différenciation", "item": "https://questionsmedicales.fr/mesh/D051796" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines d'inhibition de la différenciation - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines d'inhibition de la différenciation", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéines d'inhibition de la différenciation", "description": "Comment diagnostiquer une anomalie des protéines d'inhibition ?\nQuels tests sont utilisés pour évaluer les niveaux de ces protéines ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels marqueurs tumoraux sont associés à ces protéines ?\nPeut-on utiliser l'imagerie pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Duodenum&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéines d'inhibition de la différenciation", "description": "Quels symptômes sont liés à une surproduction de ces protéines ?\nLes symptômes varient-ils selon le type de cancer ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?\nComment les symptômes évoluent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Duodenum&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéines d'inhibition de la différenciation", "description": "Peut-on prévenir les anomalies des protéines d'inhibition ?\nY a-t-il des facteurs environnementaux à éviter ?\nLes dépistages réguliers sont-ils recommandés ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLe tabagisme influence-t-il les niveaux de ces protéines ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Duodenum&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéines d'inhibition de la différenciation", "description": "Quels traitements ciblent les protéines d'inhibition ?\nLes traitements sont-ils efficaces contre tous les cancers ?\nY a-t-il des effets secondaires aux traitements ?\nLes traitements sont-ils combinés avec d'autres thérapies ?\nComment évaluer l'efficacité du traitement ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Duodenum&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéines d'inhibition de la différenciation", "description": "Quelles complications peuvent survenir avec des niveaux anormaux ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles le pronostic ?\nY a-t-il des complications spécifiques aux traitements ?\nLes complications peuvent-elles être prévenues ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Duodenum&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéines d'inhibition de la différenciation", "description": "Quels sont les principaux facteurs de risque associés ?\nL'âge influence-t-il le risque d'anomalies ?\nLe sexe joue-t-il un rôle dans le risque ?\nLe mode de vie affecte-t-il le risque ?\nY a-t-il des maladies associées à un risque accru ?", "url": "https://questionsmedicales.fr/mesh/D051796?mesh_terms=Duodenum&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des protéines d'inhibition ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de protéines peuvent être utilisés pour diagnostiquer." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les niveaux de ces protéines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et Western blot sont couramment utilisés pour mesurer les niveaux." } }, { "@type": "Question", "name": "Les biopsies peuvent-elles aider au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les biopsies peuvent révéler des niveaux anormaux de protéines d'inhibition." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont associés à ces protéines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme le CA-125 peuvent être associés à des niveaux anormaux." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à évaluer les tumeurs, mais pas directement les protéines." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une surproduction de ces protéines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une surproduction peut entraîner des symptômes liés à des tumeurs, comme la douleur." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de cancer ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon le type de cancer associé aux protéines." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez la fatigue, la perte de poids et des douleurs inexpliquées." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être similaires à ceux d'autres maladies, rendant le diagnostic difficile." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver à mesure que la maladie progresse ou se développe." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des protéines d'inhibition ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures de prévention, comme un mode de vie sain, peuvent aider." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des agents cancérigènes peut augmenter le risque d'anomalies." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages réguliers peuvent aider à détecter des anomalies précocement." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut réduire le risque de cancer." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il les niveaux de ces protéines ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut altérer les niveaux de protéines et augmenter le risque de cancer." } }, { "@type": "Question", "name": "Quels traitements ciblent les protéines d'inhibition ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des inhibiteurs spécifiques peuvent être utilisés." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces contre tous les cancers ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'efficacité varie selon le type de cancer et le profil moléculaire." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les effets secondaires peuvent inclure des nausées, fatigue et immunosuppression." } }, { "@type": "Question", "name": "Les traitements sont-ils combinés avec d'autres thérapies ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent combinés avec la chimiothérapie ou la radiothérapie." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par imagerie et tests de suivi des niveaux de protéines." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des niveaux anormaux ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme la progression tumorale et la métastase peuvent survenir." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles avec un traitement approprié." } }, { "@type": "Question", "name": "Comment les complications affectent-elles le pronostic ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent aggraver le pronostic et réduire les chances de survie." } }, { "@type": "Question", "name": "Y a-t-il des complications spécifiques aux traitements ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains traitements peuvent entraîner des complications comme l'infection." } }, { "@type": "Question", "name": "Les complications peuvent-elles être prévenues ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être prévenues par un suivi médical régulier." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque associés ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de cancer et l'exposition à des toxines sont des facteurs clés." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'anomalies ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque d'anomalies augmente généralement avec l'âge." } }, { "@type": "Question", "name": "Le sexe joue-t-il un rôle dans le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains cancers liés aux protéines peuvent être plus fréquents chez un sexe." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Y a-t-il des maladies associées à un risque accru ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies auto-immunes peuvent augmenter le risque d'anomalies protéiques." } } ] } ] }

Sources (316 au total)

Automatic segmentation of colon, small intestine, and duodenum based on scale attention network.

Automatic segmentation of colon, small intestine, and duodenum is a challenging task because of the great variability in the scale of the target organs. Multi-scale features are the key to alleviating... A Scale Attention Module (SAM) was proposed to recalibrate multi-scale features by explicitly modeling their importance score adaptively. The SAM was introduced into the segmentation model to construc... The models were evaluated using fivefold cross-validation on 70 upper abdominal computed tomography scans of patients in a volume manner. The results showed that SANet could effectively alleviate the ... The SANet can efficiently exploit multi-scale features to alleviate the scale-variability problem and improve the segmentation performance on colon, small intestine, and duodenum of the upper abdomen....

Biliary obstruction and pancreatitis after duodenal stent placement in the descending duodenum: a retrospective study.

Metallic stents placed in the descending duodenum can cause compression of the major duodenal papilla, resulting in biliary obstruction and pancreatitis. These are notable early adverse events of duod... We retrospectively reviewed data of consecutive patients who underwent metallic stent placement in the descending duodenum for malignant gastric outlet obstruction at a tertiary referral cancer center... Sixty-five patients were included. Biliary obstruction and/or pancreatitis occurred in 12 patients (18%): 8 with biliary obstruction, 2 with pancreatitis, and 2 with both biliary obstruction and pancr... The incidence of biliary obstruction and/or pancreatitis after duodenal stent placement in the descending duodenum was non-negligible. Female sex, absence of biliary stents, and tumor invasion to the ...

Vitamin C Improves Dasatinib Concentrations Under Hypochlorhydric Conditions of the Simulated Stomach Duodenum Model.

pH-dependent drug-drug interactions (DDIs) with poorly soluble, weakly basic drugs may lead to clinical implications. Dasatinib is a tyrosine kinase inhibitor with reduced absorption in patients on ac... A dynamic, in vitro, multi-compartment, simulated stomach duodenum (SSD) model mimicking fluid volumes and transfer rates was used to investigate the concentration of BCS class IIb drugs versus time c... Significant supersaturation of dasatinib was observed in the duodenum compartment of the SSD model in FaSGF. A 90% reduction in dasatinib AUC... The SSD model serves as a good in vitro tool for assessing the effect of pH-dependent DDIs on bioavailability of weakly basic drugs with solubility/ dissolution limited absorption. Vitamin C provides ...

Obesity and overweight are linked to increased sodium-glucose cotransporter 1 and glucose transporter 5 levels in duodenum.

Prior evidence indicates that individuals with obesity have an accelerated intestinal glucose absorption. This cross-sectional study evaluated whether those with overweight or obesity display higher d... SGLT-1, GLUT-2, and GLUT-5 protein levels were assessed on duodenal mucosa biopsies of 52 individuals without diabetes categorized on the basis of their BMI as lean, with overweight, or with obesity.... Individuals with overweight and obesity exhibited progressively increased duodenal protein levels of SGLT-1 and GLUT-5 as compared with the lean group. Conversely, no differences in duodenal GLUT-2 ab... Individuals with overweight and obesity display enhanced duodenal SGLT-1 and GLUT-5 abundance, which correlates with increased postprandial glucose concentrations, insulin resistance, and hyperinsulin...

Duodenum-preserving pancreatic head resection or pancreatoduodenectomy for the surgical treatment of paraduodenal pancreatitis: a retrospective cohort study.

Paraduodenal pancreatitis (PDP) is an uncommon yet well-described type of focal chronic pancreatitis. The aim of our study was to compare the outcomes of surgical treatment of patients with PDP using ... A retrospective analysis of 153 consecutive patients with PDP was performed. Patients who were treated with either DPPHR or PD were enrolled. The primary endpoint of the study was pain control achieve... The final study population consisted of 71 patients. A total of 14 patients (19.7%) underwent pancreatoduodenectomy, and 57 (80.3%) were managed with DPPHR. Complication rate was significantly lower i... DPPHR achieves similar results in pain control as PD with a lower complication rate and shorter hospital LOS....

Unnecessary endoscopic retrograde cholangiopancreatography associated with the spontaneous passage of common bile duct stones into the duodenum: a multicenter retrospective study.

Unnecessary endoscopic retrograde cholangiopancreatography (ERCP) after spontaneous passage of common bile duct stones (CBDSs) should be avoided. This study aimed to examine the cumulative diagnosis r... This multicenter retrospective study included 1260 consecutive patients with native papilla diagnosed with CBDSs using imaging modalities. Predictive factors and cumulative diagnosis rate of spontaneo... The overall cumulative diagnosis rate of spontaneous CBDS passage was 6.2% (78/1260) during a mean interval of 5.0 days. In the multivariate analysis, CBDS sized < 6 mm on diagnostic imaging, solitary... Solitary and CBDSs sized < 6 mm on diagnostic imaging can often lead unnecessary ERCP due to spontaneous passage. Preliminary endoscopic ultrasonography immediately before ERCP is recommended, especia...

Duodenum-Preserving Pancreatic Head Resection for Benign and Premalignant Tumors-a Systematic Review and Meta-analysis of Surgery-Associated Morbidity.

Pancreatic benign, cystic, and neuroendocrine neoplasms are increasingly detected and recommended for surgical treatment. In multiorgan resection pancreatoduodenectomy or parenchyma-sparing, local ext... PubMed, Embase, and Cochrane Libraries were searched for studies reporting early surgery-related complications following pancreatoduodenectomy (PD) and duodenum-preserving total (DPPHRt) or partial (D... Comparing DPPHRt and PD, the need for blood transfusion (OR 0.20, 95% CI 0.10-0.41, p<0.01), re-intervention for serious surgery-related complications (OR 0.48, 95% CI 0.31-0.73, p<0.001), and re-oper... DPPHR for benign pancreatic tumors is associated with significantly fewer surgery-related, serious, and severe postoperative complications and lower in-hospital mortality compared to PD. Tailored use ...

Short-term clinical outcomes of laparoscopic duodenum-preserving pancreatic head resection for the management of pancreatic-head cystic neoplasms.

In this study, we aimed to investigate the short-term clinical outcomes of laparoscopic duodenum-preserving pancreatic-head resection (LDPPHR) for the management of pancreatic-head cystic neoplasms.... This retrospective study included 60 patients who were treated with pancreatic-head cystic neoplasms at the Shandong Provincial Hospital Affiliated to Shandong First Medical University from December 2... No significant difference was found between the two groups in terms of the baseline and pathological characteristics of patients (P > 0.05). The postoperative exhaust time was shorter in the LDPPHR gr... Compared with LPD, LDPPHR can decrease the postoperative exhaust time of patients, improve the short-term postoperative nutritional status, and does not decrease the safety of the perioperative period...